Mitant 12.5 Mg Capsule

Description

About Mitant 12.5 mg Capsule

Mitant 12.5 mg Capsule contains 12.5 mg of sunitinib per capsule, supplied as a pack of 7 capsules. Sunitinib is a targeted anticancer medicine — a multi-kinase inhibitor — prescribed and supervised by a cancer specialist.

How it works

Sunitinib blocks a group of enzymes, among them VEGFR, PDGFR and KIT, that tumour cells use to grow and to build the new blood vessels that feed them. Blocking these signals slows the tumour and cuts off part of its blood supply.

What it is used for

Sunitinib is used in advanced renal cell carcinoma (kidney cancer), in gastrointestinal stromal tumours where imatinib has stopped working or cannot be tolerated, and in certain pancreatic neuroendocrine tumours.

Important: this is not a neurological medicine

Sunitinib does not act on brain neurotransmitters. It is not a treatment for Parkinson’s disease, restless legs syndrome or epilepsy, and it is not a dopamine agonist. It is a cancer medicine, and must not be substituted for one.

Safety and monitoring

Serious liver injury is a recognised risk, and liver function is checked before and during treatment — report yellowing of the eyes or skin, dark urine or persistent nausea and abdominal pain at once. Tell your doctor about breathlessness, swollen ankles or an irregular heartbeat, about any bleeding, and about soreness or peeling of the palms and soles. Blood pressure and thyroid function are monitored, as blood pressure can rise and the thyroid can become underactive. The skin may turn yellowish and hair may lose its colour; both are expected and reversible.

Prescription and storage

A prescription is required, and treatment is given under the supervision of a cancer specialist. Store at room temperature, away from moisture and direct sunlight, and out of the reach of children.